Omentin-1 vs BDNF
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and BDNF (Brain-Derived Neurotrophic Factor (mature BDNF)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | BDNF |
|---|---|---|
| Category | Diabetes & Metabolic | Cognitive Enhancement |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Brain-Derived Neurotrophic Factor (mature BDNF) |
| Molecular Weight | ~35 kDa | 13,700 Da |
| Half-Life | hours | minutes to hours |
| Amino Acids | 313 | 119 aa |
| Typical Dose | No approved human dose; research use only | research-only microgram range |
| Route | IV|SC | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 8000 |
| Research Status | Pre-clinical | Pre-clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
BDNF Benefits
- ✓neurogenesis
- ✓synaptogenesis
- ✓LTP support
- ✓neuronal survival
Omentin-1 Dosing
not established|not established
BDNF Dosing
0.1-1 µg local or intranasal research delivery|viral or protein infusion models|acute or repeated plasticity protocols
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
BDNF Side Effects
- ⚠off-target neuroexcitation
- ⚠headache-like effects
- ⚠unknown systemic protein effects
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
BDNF
BDNF is repeatedly associated with learning, long-term potentiation, and recovery from neurologic injury in preclinical literature. Direct protein delivery is difficult, so most studies focus on pathways that raise endogenous BDNF or on localized experimental administration.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.